Free Trial

Perspective Therapeutics (CATX) Stock Price, News & Analysis

-0.65 (-5.16%)
(As of 03:39 PM ET)
Today's Range
50-Day Range
52-Week Range
425,980 shs
Average Volume
604,456 shs
Market Capitalization
$744.01 million
P/E Ratio
Dividend Yield
Price Target

Perspective Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
58.5% Upside
$19.00 Price Target
Short Interest
Dividend Strength
News Sentiment
Insider Trading
Acquiring Shares
$385,487 Bought Last Quarter
Proj. Earnings Growth
From ($1.00) to ($1.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.88 out of 5 stars

Medical Sector

767th out of 914 stocks

Surgical & Medical Instruments Industry

87th out of 99 stocks

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

CATX Stock Price History

CATX Stock News Headlines

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Perspective Therapeutics: Q1 Earnings Snapshot
See More Headlines
Receive CATX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.43 million
Book Value
$2.67 per share


Free Float
Market Cap
$784.48 million
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Johan M. Spoor (Age 52)
    CEO & Director
    Comp: $855.78k
  • Mr. Jonathan R. Hunt (Age 57)
    CFO & Co-Principal Financial Officer
    Comp: $944.35k
  • Dr. Markus Puhlmann M.B.A. (Age 58)
    M.D., Chief Medical Officer
    Comp: $633.14k
  • Mr. Shane Cobb
    Executive Vice President of Operations
  • Mr. Mark J. Austin CPA (Age 37)
    VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary
  • Dr. Michael K. Schultz Ph.D.
    Chief Science Officer
  • Mr. Andrew Bright
    Executive Vice President of Brachytherapy
  • Mr. Amos Hedt BA
    PGradDip, Chief Business Strategy Officer
  • Dr. Frances L. Johnson M.D.
    Chief Innovation Officer
  • Mr. David Hauser Ph.D.
    Senior Vice President of Clinical Operations

CATX Stock Analysis - Frequently Asked Questions

How have CATX shares performed this year?

Perspective Therapeutics' stock was trading at $11.90 at the beginning of the year. Since then, CATX shares have increased by 0.8% and is now trading at $11.99.
View the best growth stocks for 2024 here

How were Perspective Therapeutics' earnings last quarter?

Perspective Therapeutics, Inc. (NYSE:CATX) announced its earnings results on Wednesday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. The firm had revenue of $0.33 million for the quarter.

When did Perspective Therapeutics' stock split?

Perspective Therapeutics shares reverse split on Monday, June 17th 2024. The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Perspective Therapeutics?

Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CATX) was last updated on 7/17/2024 by Staff

From Our Partners